Welcome to LookChem.com Sign In|Join Free
  • or
Cyclohexanecarboxylic acid, 4-(aminomethyl)-, monopotassium salt, trans- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

140218-27-5

Post Buying Request

140218-27-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

140218-27-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 140218-27-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,0,2,1 and 8 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 140218-27:
(8*1)+(7*4)+(6*0)+(5*2)+(4*1)+(3*8)+(2*2)+(1*7)=85
85 % 10 = 5
So 140218-27-5 is a valid CAS Registry Number.

140218-27-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name potassium tranexamate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:140218-27-5 SDS

140218-27-5Downstream Products

140218-27-5Relevant academic research and scientific papers

SYSTEM AND METHOD FOR DELIVERING PROTEASE INHIBITORS

-

Paragraph 0183, (2014/08/19)

The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 140218-27-5